The special regulatory regime for drug advertising

Drugs are special goods tied to life and health, so drug advertising faces the strictest review and limits of any commercial advertising. China applies a "review-then-publish" dual regime: ads must be reviewed and approved by the provincial drug authority (obtaining an approval number) before publication, and both the drug authority and the market regulator may supervise content afterwards.

Key legal bases

  • Advertising Law, Art. 15–17 — special provisions for drug and device ads
  • Drug Administration Law, Art. 88–91 — approval and content limits
  • Interim Measures on Review of Drug, Device, Health Food and FSMP Advertising
  • Measures for the Administration of Internet Advertising

Prescription vs. OTC — two very different regimes

CategoryPermitted mediaContent requirements
Prescription (Rx)Only in medical/pharmaceutical professional journals jointly designated by the health and drug authorities. Advertising to the public via mass media (TV, radio, newspapers, internet, outdoor) is prohibited in any form.Content follows the approved label, and must state "for medical and pharmaceutical professionals only".
OTCMass-media advertising permitted.Content follows the approved label, must show the OTC mark and "use as directed on the label or under a pharmacist's guidance".

Key compliance trap: "soft promotion" of Rx drugs — through patient-education articles, health content or expert interviews — sits in a regulatory grey zone increasingly treated as disguised Rx advertising. Rx "science-popularisation" content via WeChat accounts, Douyin doctors and other new-media KOLs is now a priority enforcement target.

Red lines in drug ad content

  • No false or misleading content
  • No absolute claims or guarantees such as "best efficacy", "cure guaranteed" or "safe, no side effects"
  • No "cure rate" or "efficacy rate" figures (unless adequately evidenced and approved)
  • No comparisons with the efficacy or safety of other drugs
  • No endorsement using state organs, research bodies, academic institutions, industry associations or the names/images of experts, doctors, pharmacists or patients — a commonly-overlooked prohibition: no patient "testimonials" or doctor "endorsements"
  • No absolute terms such as "safe" or "no toxic side effects"
  • No inducements such as "hot-selling", "rushed purchase", "free trial" or "free gift"

Online drug information and online sales

Internet Drug Information Service licence

Providing drug (including device) information to users over the internet requires an Internet Drug Information Service Qualification Certificate. Operating without one draws orders to stop, warnings and fines.

Online drug sales

  • Prohibited online: vaccines, blood products, anaesthetics, psychotropics, toxic medical drugs, radioactive drugs and drug precursor chemicals.
  • Rx online sales: permitted but strictly on prescription — "prescription first, then drug". Platforms must verify prescriptions; "AI prescribing" and "no-prescription sales" are banned.
  • Third-party platform duties: platforms (JD Health, AliHealth, etc.) must verify and continuously manage merchants.

Consequences of ad violations

  • Administrative: orders to stop, eliminate impact, and fines of 3–5× the ad fee (or CNY 200,000–1,000,000 where the fee is incalculable); in serious cases revocation of the licence or ad approval number, with a one-year bar on further applications.
  • Civil liability: false ads that harm consumers trigger civil liability of the advertiser.
  • Credit sanctions: serious violations are publicly listed for joint punishment.

How we help

  1. Pre-publication review: Rx/OTC classification, prohibited-content screening and approval-number applications and renewals.
  2. Internet licence applications: materials, compliance plans and on-site inspection support.
  3. Online-sales compliance: platform qualification review and compliance management.
  4. New-media guidance: boundaries for WeChat, Douyin and Xiaohongshu content.
  5. Penalty response: hearings, statements, defences and remediation after enforcement notices.